Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260

Benzinga · 1d ago
Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $235 to $260.